AstraZeneca Pharmaceuticals LP - Tumor Board: Integrating Immunotherapy With Definitive and Perioperative Radiation Strategies in Stage I-III NSCLC
Speaker(s)
Joe Chang, MD, PhD, MS, FASTRO - MD Anderson Cancer Center
Nitin Ohri, MD, MS - Albert Einstein College of Medicine
Hossein Borghaei, DO, MS - Fox Chase Cancer Center
session DESCRIPTION
This educational activity is directed toward ASTRO congress attendees, including an audience of radiation oncologists (primary), with medical oncologists, thoracic surgeons, APPs, oncology nurses, and pharmacists managing stage I-III NSCLC. Dinner will be provided. For more information, please visit www.astro.org/ISS.
learning objectives
Describe the rationale for combining immunotherapy and radiation in NSCLC.
Evaluate trial evidence for immunotherapy and targeted therapy with radiation in stages I-III.
Apply MDT input and EGFR status to treatment decisions.
Manage irAEs in combined modality.
Credits
| AMA PRA Category 1 Credits: | Physicians’ Education Resource®, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™ and 1.5 contact hours for nurses. |